Close
Novel Immunotherapy in Dogs With Melanoma and Mast Cell Tumors

Trial Specifics

BluePearl – Overland Park will be participating in a funded clinical trial designed to evaluate the safety and preliminary anti-cancer activity of a novel, monoclonal antibody in dogs with measurable cancer. An estimated 20 client-owned dogs with melanoma or mast cell tumors will be enrolled. The antibody is administered IV by the study staff every 14 days for up to 10 treatments. No placebo is used in this trial. Visits will be required every 2 weeks for a total trial period of 140 days.

Trial Funding

The trial is fully funded for the duration of the study (140 days), including the antibody and trial-related procedures.

Trial Eligibility

Dogs with one of the following cancers may be enrolled if they meet the specific criteria for each cancer:

Mast Cell Tumors
  1. At least one measurable skin tumor +/- metastatic lymph node(s) > 2 cm
  2. No intraabdominal metastasis
  3. Prior therapy accepted with washout times to be discussed with the participating site
Melanoma
  1. At least one measurable malignant tumor in the oral cavity, digit, skin +/- metastatic lymph node > 2 cm
  2. No pulmonary metastasis
  3. Prior therapy accepted with washout times to be discussed with site

For more information, or if you have a patient who may meet the above requirements, please contact Beth Rogers in our Overland Park hospital at 913.642.9563.